Demethylating Agent 5-Aza-2′-Deoxycytidine Enhances Susceptibility of Bladder Transitional Cell Carcinoma to Cisplatin

Urology

Volumn 71, Issue 6, 2008, Pages 1220-1225

  Shang, Donghao ^a   Liu, Yuting ^a   Matsui, Yoshiyuki ^a   Ito, Noriyuki ^a   Nishiyama, Hiroyuki ^a   Kamoto, Toshiyuki ^a   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CASPASE; CISPLATIN; CYCLINE; PROTEIN P53;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER SUSCEPTIBILITY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DEMETHYLATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG INHIBITION; DRUG POTENTIATION; ENZYME ACTIVITY; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AZACITIDINE; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CISPLATIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 44449110220     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2007.11.029     Document Type: Article

References (21)

1. Solsona E., Iborra I., Dumont R., et al. The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer. J Urol 164 (2000) 685-689
2. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today: a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690-696
3. Nieuwenhuijzen J.A., Bex A., Meinhardt W., et al. Neoadjuvant methotrexate, vinblastine, doxorubicin and cisplatin for histologically proven lymph node positive bladder cancer. J Urol 174 (2005) 80-85
4. Lubbert M., Daskalakis M., Kunzmann R., et al. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2′-deoxycytidine (decitabine). Leuk Res 28 (2004) 1267-1271
5. Momparler R.L., Bouffard D.Y., Momparler L.F., et al. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs 8 (1997) 358-368
6. Gomyo Y., Sasaki J., Branch C., et al. 5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23 (2004) 6779-6787
7. Kaminski R., Kozar K., Niderla J., et al. Demethylating agent 5-aza-2′-deoxycytidine enhances expression of TNFRI and promotes TNF-mediated apoptosis in vitro and in vivo. Oncol Rep 12 (2004) 509-516
8. Berenbaum M.C. A method for testing for synergy with any number of agents. J Infect Dis 137 (1978) 122-130
9. Shang D., Ito N., Kamoto T., and Ogawa O. Demethylating agent 5-aza-2′-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel. Urology 69 (2007) 1007-1012
10. Alleman W.G., Tabios R.L., Chandramouli G.V., et al. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2′-deoxycytidine. Clin Cancer Res 10 (2004) 7011-7021
11. Juttermann R., Li E., and Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 91 (1994) 11797-11801
12. Plumb J.A., Strathdee G., Sludden J., et al. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60 (2000) 6039-6044
13. Furihata M., Takeuchi T., Ohtsuki Y., et al. Genetic analysis of hMLH1 in transitional cell carcinoma of the urinary tract: promoter methylation or mutation. J Urol 165 (2001) 1760-1764
14. Maruyama R., Toyooka S., Toyooka K., et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 61 (2001) 8659-8663
15. Schlechte H.H., Schnorr D., Loning T., et al. Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers-investigation by temperature gradient gel electrophoresis (TGGE). J Urol 157 (1997) 1049-1053
16. Kakehi Y., Ozdemir E., Habuchi T., et al. Absence of p53 overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn J Cancer Res 89 (1998) 214-220
17. Zhu W.G., Hileman T., Ke Y., et al. 5-Aza-2′-deoxycytidine activates the p53/p21Waf1/Cip1 pathway to inhibit cell proliferation. J Biol Chem 279 (2004) 15161-15166
18. Nieto M., Samper E., Fraga M.F., et al. The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine. Oncogene 23 (2004) 735-743
19. Takaoka A., Hayakawa S., Yanai H., et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424 (2003) 516-523
20. Mohiuddin M., Chendil D., Dey S., et al. Influence of p53 status on radiation and 5-fluorouracil synergy in pancreatic cancer cells. Anticancer Res 22 (2002) 825-830
21. Raghavan D., Pearson B., Watt W.H., et al. Cytotoxic chemotherapy for advanced bladder cancer: cisplatin-containing regimens. Semin Oncol 18 (1991) 56-63